Protective Effect of Human Umbilical Cord Mesenchymal Stem Cells in Glucocorticoid-induced Osteonecrosis of Femoral Head

Abstract

Objective

To evaluate the effect of human umbilical cord mesenchymal stem cells (hUC-MSCs) on preventing rats from glucocorticoid-induced osteonecrosis of femoral head (GCONFH) in the early stage in vivo and to investigate the possible mechanism of hUC-MSCs in regulating the balance of osteogenesis and adipogenesis.

Methods

All rats were randomly divided into 3 groups: control group (C group), model group (M group), and intervention group (I group). The model of GC-ONFH was developed by a sequential administration of lipopolysaccharide and methylprednisolone. The rats in the I group were treated with caudal vein injection of hUC-MSCs. Six weeks later, the blood samples were obtained to measure the activity of alkaline phosphatase (ALP) and the content of triglyceride (TG) in serum, and the femoral heads were harvested and observed by hematoxylin-eosin staining, Micro-CT, Western blot and real-time quantitative polymerase chain reaction.

Results

After intervention of hUC-MSCs, the necrosis rate of femoral head decreased from 83% (10/12) to 33% (4/12), the rate of empty bone lacuna was significantly decreased, the activity of ALP increased significantly, the content of TG decreased significantly, the bone density increased obviously, the expression of RUNX2 and Col I increased significantly and the expression of PPARγ decreased significantly.

Conclusion

These results revealed that caudal vein injection of hUC-MSCs can effectively reduce the incidence of GC-ONFH in rats by increasing ALP activity and reducing TG content in serum, increasing bone mineral density, promoting the expression of RUNX2 and Col I, and inhibiting the expression of PPARγ.

Keywords

glucocorticoid-induced osteonecrosis of femoral head / human umbilical cord mesenchymal stem cell / RUNX2 / Col I / PPARγ

References

[1] FukushimaW, FujiokaM, KuboT, et al.. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res, 2010, 468(10): 2715-2724

[2] ChenJ, ShiZD, JiX, et al.. Enhanced osteogenesis of human mesenchymal stem cells by periodic heat shock in self-assembling peptide hydrogel. Tissue Eng Part A, 2013, 19(5-6): 716-728

[3] StocklS, GottlC, GrifkaJ, et al.. Sox9 Modulates proliferation and expression of osteogenic markers of adipose-derived stem cells (ASC). Cell Physiol Biochem, 2013, 31(4-5): 703-717

[4] ZhangB, YangS, SunZ, et al.. Human mesenchymal stem cells induced by growth differentiation factor 5: an improved self-assembly tissue engineering method for cartilage repair. Tissue Eng Part C Methods, 2011, 17(12): 1189-1199

[5] WakitaniS, SaitoT, CaplanAI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve, 1995, 18(12): 1417-1126

[6] KuangMJ, HuangY, ZhaoXG, et al.. Exosomes derived from Wharton's jelly of human umbilical cord mesenchymal stem cells reduce osteocyte apoptosis in glucocorticoid-induced osteonecrosis of the femoral head in rats via the miR-21-PTEN-AKT signalling pathway. Int J Biol Sci, 2019, 15(9): 1861-1871

[7] WilsonA, WebsterA, GeneverP. Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine. Regen Med, 2019, 14(6): 595-611

[8] YanZ, HuangD, GuoC, et al.. Fate of mesenchymal stem cells transplanted to osteonecrosis of femoral head. J Orthop Res, 2009, 27(4): 442-446

[9] ZhaoD, CuiD, WangB, et al.. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone, 2012, 50(1): 325-330

[10] ChenC, YangS, FengY, et al.. Impairment of two types of circulating endothelial progenitor cells in patients with glucocorticoid-induced avascular osteonecrosis of the femoral head. Joint Bone Spine, 2013, 80(1): 70-76

[11] MurataM, KumagaiK, MiyataN, et al.. Osteonecrosis in stroke-prone spontaneously hypertensive rats: effect of glucocorticoid. J Orthop Sci, 2007, 12(3): 289-295

[12] MotomuraG, YamamotoT, MiyanishiK, et al.. Bone marrow fat-cell enlargement in early steroid-induced osteonecrosis—a histomorphometric study of autopsy cases. Pathol Res Pract, 2005, 200(11-12): 807-811

[13] HuangZ, ChengC, CaoB, et al.. Icariin Protects against Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Rats. Cell Physiol Biochem, 2018, 47(2): 694-706

[14] BoseR, MoorsM, TofighiR, et al.. Glucocorticoids induce long-lasting effects in neural stem cells resulting in senescence-related alterations. Cell Death Dis, 2010, 1: e92

[15] FranceschiRT, XiaoG. Regulation of the osteoblastspecific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem, 2003, 88(3): 446-454

[16] KarsentyG. The genetic transformation of bone biology. Genes Dev, 1999, 13(23): 3037-3051

[17] ShuiC, SpelsbergTC, RiggsBL, et al.. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res, 2003, 18(2): 213-221

[18] KomoriT, YagiH, NomuraS, et al.. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 1997, 89(5): 755-764

[19] ShaoD, LazarMA. Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem, 1997, 272(34): 21 473-21 478

[20] LiX, CuiQ, KaoC, et al.. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone, 2003, 33(4): 652-659

[21] ValentiMT, GarbinU, PasiniA, et al.. Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPARgamma2 expression in MSCs-like of osteoporotic patients. PLoS One, 2011, 6(6): e20363

[22] ZhangL, SuP, XuC, et al.. Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARgamma expression and enhancing Runx2 expression. J Pineal Res, 2010, 49(4): 364-372

[23] FenskyF, ReichertJC, TraubeA, et al.. Chondrogenic predifferentiation of human mesenchymal stem cells in collagen type I hydrogels. Biomed Tech (Berl), 2014, 59(5): 375-383

[24] AndrioloL, MerliG, TobarC, et al.. Regenerative therapies increase survivorship of avascular necrosis of the femoral head: a systematic review and metaanalysis. Int Orthop., 2018, 42(7): 1689-1704

[25] LIT, XiaMX, GaoYY, et al.. Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy. Expert Opin Biol Ther, 2015, 15(9): 1293-1306

[26] DiaoY, MaQ, CuiF, et al.. Human umbilical cord mesenchymal stem cells: osteogenesis in vivo as seed cells for bone tissue engineering. J Biomed Mater Res A, 2009, 91(1): 123-131

[27] MarupanthornK, TantrawatpanC, TantikanlayapornD, et al.. The Effects of TNF-alpha on Osteogenic Differentiation of Umbilical Cord Derived Mesenchymal Stem Cells. J Med Assoc Thai, 2015, 98Suppl3: S34-40

[28] QuZ, GuoS, FangG, et al.. AKT Pathway Affects Bone Regeneration in Nonunion Treated with Umbilical Cord-Derived Mesenchymal Stem Cells. Cell Biochem Biophys, 2015, 71(3): 1543-1551

[29] QuZ, GuoL, FangG, et al.. Biological characteristics and effect of human umbilical cord mesenchymal stem cells (hUC-MSCs) grafting with blood plasma on bone regeneration in rats. Cell Biochem Biophys, 2012, 63(2): 171-181